T RANSCRIPTION OF steroid hydroxylase genes is reg-
ulated by the release of the peptide hormone ACTH from the anterior pituitary and the subsequent increase in intracellular cAMP (1, 2) . The actions of ACTH/cAMP are mediated via a PKA-dependent pathway (3) , which leads to an increase in the transcription of steroid hydroxylase genes assuring maintenance of optimal steroidogenic capacity in the adrenal cortex. This increase in the transcriptional activity of steroid hydroxylase genes has been found to occur in a cAMP-dependent pathway that is distinct from the classical cAMP response, which is an immediate and rapid increase in gene transcription resulting from cAMP response elementbinding proteins bound to cAMP response element. The cAMP-dependent increases in the transcription of steroid hydroxylase genes occurs over a longer time period after stimulation with ACTH/cAMP via the binding of various transcription factors to cAMP-responsive sequences (CRS) (4 -6) . Despite the coordinate increase in the transcription of all steroidogenic genes expressed in the adrenal cortex, the CRS regions in the various steroid hydroxylase genes and the specific DNA-binding proteins that interact with these sequences have been found to be species, tissue, and gene specific (4 -6) .
Transcriptional regulation of the bovine CYP17 (bCYP17; 17␣-hydroxylase/17,20-lyase) gene has been extensively studied, and ACTH/cAMP-dependent transcription has been found to occur via two cAMP regulatory sequences (CRS1 and CRS2) in the 5Ј-flanking region of the gene. CRS1, which lies approximately Ϫ243/Ϫ225 upstream of the transcriptional initiation site, binds the homeodomain proteins Pbx1, Meis1, and Pknox (7) . CRS2 (Ϫ80/Ϫ40 of bCYP17), on the other hand, binds the orphan nuclear receptors chicken ovalbumin promoter-transcription factor and steroidogenic factor-1 (SF-1) in a mutually exclusive manner, where chicken ovalbumin promoter-transcription factor acts to suppress transcription and SF-1 stimulates gene expression (8) .
We (8a) and others (9) have recently found that cAMPdependent transcription of the human CYP17 gene occurs via a single CRS located from Ϫ57/Ϫ38 upstream of the transcriptional initiation site. Further, we have identified the transcription factors interacting with this region showing that SF-1, p54
nrb /NonO and poly-pyrimidine tract-binding protein-associated splicing factor (PSF) bind both each other and the human CYP17 (hCYP17) promoter, thereby conferring cAMP responsiveness to the hCYP17 gene. p54 nrb is the human homolog of murine NonO, a ubiquitously expressed non-POU domain-containing, octamer-binding protein that contains both DNA-and RNA-binding domains (10) . PSF is an essential mammalian splicing factor (11) that has also been shown to repress porcine CYP11A (cholesterol side-chain cleavage cytochrome P450) (12) . Using EMSA we demonstrated that cAMP stimulates increased binding intensity of a SF-1-p54 nrb /NonO-PSF complex to the Ϫ57/Ϫ38 region of the hCYP17 promoter (8a). This cAMP-inducible binding was found to be cell line selective, cycloheximide sensitive, and observable within 2 h after cAMP stimulation. The transcription of steroid hydroxylase genes has been extensively studied in various species (1, 2, 13) . Each gene contains unique CRS that interact with specific transcription factors, and this interaction acts to confer basal and cAMPdependent transcriptional activity. We have recently found that the cAMP-dependent transcription of the hCYP17 gene is regulated by the concerted action of SF-1, PSF, and p54 nrb / NonO binding to the Ϫ57/Ϫ38 region of the gene's promoter (8a). This work also detected for the first time in the study of steroid hormone biosynthesis that cAMP can induce the cycloheximide-sensitive binding of transcription factors to a responsive sequence in the promoter. The aim of the present study was to determine the mechanism by which cAMP evokes an increase in the binding intensity of SF-1, PSF, and p54 nrb /NonO to the Ϫ57/Ϫ38 region of the hCYP17 5Ј flank.
Materials and Methods Reagents
(Bu) 2 cAMP and hydrogen peroxide were obtained from Sigma (St. Louis, MO). Okadaic acid (OA), PD98059, PKI-(6 -22) peptide, and sodium orthovanadate were obtained from Calbiochem (San Diego, CA). Peroxyvanadate (PV) was prepared by mixing equal concentrations (12 mm) of hydrogen peroxide with sodium orthovanadate before treatment. OA is an inhibitor of serine/threonine phosphatase activity, and PV inhibits phosphotyrosine phosphatase activity. PD98059 inhibits the MAPK cascade, and the PKI-(6 -22) peptide inhibits PKA.
Preparation of plasmid constructs
A plasmid containing a 57-bp fragment of the hCYP17 promoter fused to the luciferase gene in the pGL3 vector (Promega Corp., Madison, WI) was generated by ligating double-stranded oligonucleotides that corresponded to Ϫ57/Ϫ2 of the hCYP17 promoter upstream of the luciferase gene in the pGL3 vector. Data obtained from luciferase assays (relative luciferase light units, RLU) were normalized to the protein content of each sample.
Cell culture, transient transfection, and luciferase assay
H295R adrenocortical cells (14) were cultured in DMEM/F-12 medium (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% Nu-Serum I (Collaborative Biomedical Products, Bedford, MA), 0.5% ITS Plus (Collaborative Biomedical Products), and antibiotics. Twenty-four hours before transfection, cells were subcultured onto sixwell culture dishes. Plasmids were transfected into H295R cells using the Effectene nonliposomal lipid transfection reagent (QIAGEN, Valencia, CA) for 24 h, followed by an additional 2-to 12-h incubation in the presence or absence of 1 mm (Bu) 2 cAMP, OA (5-50 nm), PV (5-50 m), 10 m protein kinase inhibitor [PKI- (6 -22) peptide], or 25 m PD98059. Cells were harvested, and cellular extracts were prepared for luciferase assays (Promega Corp.) and protein concentration determination (Pierce Chemical Co., Rockford, IL).
EMSA
For nuclear extract isolation, cells were subcultured onto 100-mm dishes for 24 h, followed by incubation with (Bu) 2 cAMP, OA, PV, PKI, or PD98059 for 2-12 h. Nuclear extracts were prepared according to the method of Dignam et al. (15) . Double-stranded oligonucleotides were labeled with [␣-32 P]dCTP (3000 Ci/mmol; NEN Life Science Products, Boston, MA) by a fill-in reaction using DNA polymerase I, Klenow fragment (Stratagene). Five micrograms of nuclear protein, 0.5 g poly(dI-dC), 50 g BSA, and 32 P-labeled probe (10,000 cpm) were mixed in 25 l binding buffer [20 
RNA isolation, Northern blotting, and hybridization conditions
H295R cells were subcultured onto six-well plates and treated with (Bu) 2 cAMP in the presence or absence of kinase (PKI and PD98059) and phosphatase (OA and PV) inhibitors for periods ranging from 4 -24 h. Total RNA was prepared from treated cells by acid-phenol extraction (16) . RNA concentrations were determined by absorbance at 260 nm. For Northern blot assays (17) , RNA (10 g) was fractionated by agarose (1%) gel electrophoresis in the presence of 5% formaldehyde and transferred to nylon transfer membrane filters (Hybond-N ϩ , Amersham Pharmacia Biotech, Piscataway, NJ). A 1.2-kb cDNA fragment of hCYP17 was used to detect hCYP17 mRNA expression. Results were normalized to the content of glyceraldehyde-3-phosphate dehydrogenase (GAP) mRNA. cDNA probes were labeled with [␣-32 P]dCTP by random primer labeling (Prime It II, Stratagene). Blots were hybridized overnight at 42 C in a 2ϫ SSC solution containing 50% formamide, 5ϫ Denhardt's solution, 2% SDS, 100 g/ml denatured single-stranded salmon sperm DNA, and 32 P-labeled cDNA probes. The hybridized membranes were sequentially washed twice for 10 min each time in 2ϫ SSC/0.2% SDS and twice for 5 min each time in 0.2ϫ SSC/0.2% SDS at 42 C. The amount of probe bound to the filter was quantitated using PhosphorImager and ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA).
In vitro dephosphorylation of nuclear proteins
Nuclear extracts (5 g) isolated from unstimulated H295R cells were incubated with recombinant protein phosphatase , (-PPase; Calbiochem, La Jolla, CA). The reaction was carried out for 20 min at 30 C in buffer comprised of 50 mm Tris-Cl (pH 7.8), 5 mm dithiothreitol, 2 mm MnCl 2 , and 100 g/ml BSA. A range of concentrations of -PPase from 1-200 U was used.
In vivo labeling and immunoprecipitation
For in vivo labeling, H295R cells were cultured in 100-mm dishes. The medium was changed to phosphate-free DMEM containing 1.5 mCi [ 32 P]orthophosphate (NEN Life Science Products). Cells were grown for 16 h before harvesting for immunoprecipitation. Some cells were stimulated with 1 mm (Bu) 2 cAMP for 12 h before harvest. Radiolabeled cells were harvested, and nuclear extracts were isolated as described above. For immunoprecipitation assays nuclear proteins were incubated with anti-SF-1 antiserum or anti-NonO antiserum and protein A-Sepharose beads overnight at 4 C with rotation. The mixture was then centrifuged, and the supernatant was removed. Beads were washed three times and resuspended in SDS-PAGE gel loading buffer for SDS-PAGE (8% gel) and Western blotting. Western blots were subjected to audioradiography to detect 32 P-labeled proteins. For detection of SF-1 and p54 nrb / NonO, membranes were blocked overnight in TBS-Tween 20 containing 5% BSA, followed by incubation with anti-SF-1 (a gift from Dr. K. Morohashi, National Institute for Basic Biology, Okazaki, Japan) or anti-NonO (donated by Dr. P. W. Tucker, University of Texas, Austin, TX) antisera. Membranes were washed in TBS-Tween 20 and incubated with protein G-horseradish peroxidase conjugate (Bio-Rad Laboratories, Inc., Hercules, CA). Protein expression was detected using the ECL Plus Western blot detection kit (Amersham Pharmacia Biotech).
Statistical analysis
Data from Northern blots were expressed as a percentage of the mean of the control group in each experiment. Data obtained from transfection assays were expressed as relative light units per microgram of protein.
One-way ANOVA and the Newman-Keuls test were used to determine differences among treatment groups.
Results

Role of MAPK on cAMP
Inducible binding of the SF-1/p54 nrb /NonO/PSF complex to Ϫ57/Ϫ38 of the hCYP17 promoter. We have demonstrated that the interaction of SF-1, p54 nrb /NonO, and PSF with the Ϫ57/Ϫ38 region of the hCYP17 promoter is essential for cAMP-dependent transcription (8a). Further, binding studies (EMSA) using nuclear extracts isolated from H295R cells treated with (Bu) 2 cAMP have shown cAMP-inducible binding of SF-1, PSF, and p54 nrb /NonO to this Ϫ57/Ϫ38 region (8a). The mechanism by which cAMP evokes an increase in the binding intensity of the proteins is unclear. However, we speculate from the results reported here that changes in the phosphorylation state of SF-1, p54 nrb /NonO, and/or PSF account for the cAMP-dependent increase in binding intensity.
Studies by Hammer et al. (18) demonstrated that SF-1 can be phosphorylated on serine 203 by MAPK in a PKA-independent manner and enhance basal transcriptional activity. Thus, in the present study our goal was to determine whether cross-talk between the PKA and MAPK pathways conveys the cAMP-inducible binding to the Ϫ57/Ϫ38 region of the hCYP17 5Ј flank. Specifically, of numerous MAPK family members (19 -21) we postulated that the p42/p44MAPK pathway (ERK1 and ERK2) (22, 23) may play a role in ACTH/ cAMP-dependent transcriptional regulation of hCYP17. The effects of the PKA inhibitor PKI (10 m) and the MAPK inhibitor PD98059 (25 m) on cAMP-inducible binding of nuclear proteins to a Ϫ57/Ϫ38 radiolabeled double-stranded oligonucleotide were examined by EMSA. As shown in Fig.  1A , three DNA-protein complexes are formed. Our previous studies have shown (8a) that SF-1 or p54 nrb /NonO comprise the lower, fastest migrating band, p54 nrb /NonO and PSF comprise the middle complex, and SF-1, p54 nrb /NonO, and PSF bind to each other to comprise the upper DNA-protein complex. Transcription is repressed when PSF in the upper complex binds to the corepressor mSin3A. When nuclear extracts isolated from H295R cells treated with 1 mm (Bu) 2 cAMP for 2 or 12 h were used, increased binding intensity of the upper DNA-protein complex was observed (Fig. 1A, lanes 2 and 8) . Unexpectedly, treatment of cells for 12 h with 25 m PD98059 alone also increased the binding of the upper complex (Fig. 1A, lanes 6 and 12) . When using nuclear extracts isolated from cells that were treated with both (Bu) 2 cAMP and PD98059 for 12 h, the cAMP-inducible binding of the upper complex was further increased (Fig. 1A , lane 10). No effect of PD98059 was seen on the formation of the lower bands, nor was coadministration of 10 m PKI able to alter the formation of any of the bands. Therefore, we conclude that PKA does not phosphorylate SF-1, p54 nrb / NonO, or PSF directly, but plays some other role in the pathway, perhaps by phosphorylating an intermediary protein.
We (8a) and others (9) have demonstrated using transient transfection assays that approximately the first 57 bp upstream of the transcription initiation site of hCYP17 are essential to confer both basal and cAMP-mediated transcription. Thus, based on our EMSA findings that PD98059, the MAPK inhibitor, can mimic the cAMP-inducible binding of the upper complex, we decided to determine whether PD98059 can also activate transcription of a promoterreporter construct containing the first 57 bp of hCYP17 fused to the luciferase gene. Figure 1B shows that transfection of 57-pGL3 increases luciferase activity by approximately 4-fold over pGL3 alone. Treating the cells with 1 mm (Bu) 2 cAMP for 12 h further increased transcriptional activity, as did 25 m PD98059 (Fig. 1B) . However, the effect of coadministration of (Bu) 2 cAMP and PD98059 was not additive. In addition to inducing the transcriptional activity of transiently transfected hCYP17 promoter-reporter constructs, 25 m PD98059 increased the expression of endogenous hCYP17 mRNA (Fig. 1, C and D) . A representative Northern (n ϭ 3/group) is shown in Fig. 1C , and densitometric analysis (Fig. 1D) demonstrates a 25-fold increase in hCYP17 mRNA accumulation after exposure to (Bu) 2 cAMP and a 10-fold induction with PD98059 treatment alone. PKI significantly suppressed the cAMP-dependent increase in hCYP17 mRNA expression, emphasizing that PKA is essential for induced hCYP17 transcription, but not via the direct phosphorylation of SF-1, p54 nrb /NonO, or PSF (see below).
Inhibition of phosphatase activity attenuates the cAMPinducible binding to Ϫ57/Ϫ38 of the hCYP17 promoter
As we were unable to inhibit the cAMP-inducible formation of the upper DNA-protein complex by inactivating the MAPK pathway, we hypothesized that dephosphorylation could be the key event that conveys cAMP-evoked increased binding intensity. To test this idea we performed EMSA on nuclear extracts that were isolated from cells that were treated with (Bu) 2 cAMP in the presence and absence of the phosphatase inhibitors OA (10 nm) and PV (50 m).
Two hours after treating cells with both 1 mm (Bu) 2 cAMP and 10 nm OA, significantly less cAMP-inducible binding of the upper complex was observed (Fig. 2, lane 3) . PV also significantly attenuated the increase in binding intensity of the upper complex that was evoked by (Bu) 2 cAMP treatment (lane 4). At the 12-h point, OA was still effective in inhibiting cAMP-inducible binding (lane 9). Neither agent had a significant effect on the formation of the upper complex when administered in the absence of (Bu) 2 cAMP. These findings show that removal of a phosphate group from SF-1, p54 nrb / NonO, and/or PSF probably mediates the cAMP-dependent increase in binding of the SF-1/p54 nrb /NonO/PSF complex to the Ϫ57/Ϫ38 region of the hCYP17 promoter.
Effect of phosphatase inhibition on the transcriptional activity of 57-pGL3
In addition to examining the role of dephosphorylation in cAMP-inducible binding of proteins to the hCYP17 promoter, we investigated the effects of the phosphatase inhibitors on the cAMP-dependent transcriptional activity of 57-pGL3 (Fig. 3) . As shown in Fig. 3A , transfection of cells with 57-pGL3 increased luciferase activity compared with the pGL3 empty vector by 5-fold, and (Bu) 2 cAMP treatment further stimulated transcriptional activity 2.5-fold. Treatment of the transfected cells with concentrations of OA ranging from 5-50 nm produced a dose-dependent decrease in the cAMP-dependent increase in transcription.
In similar experiments the effect of the tyrosine phosphatase inhibitor PV on (Bu) 2 cAMP-mediated 57-pGL3 transcriptional activity was examined (Fig. 3B) . Like OA, peroxyvanadate (5-50 m) was also effective in producing a dose-dependent attenuation of the cAMP-dependent luciferase activity of the 57-pGL3 construct. No significant effect of treating the cells with PV alone was detected (Fig. 3B) .
Phosphatase inhibitors attenuate cAMP-mediated transcription of endogenous hCYP17 in H295R cells
The effect of OA on the cAMP-mediated increase in endogenous hCYP17 mRNA expression was also examined. Cells were treated for 12 h with 1 mm (Bu) 2 cAMP with or without OA (5, 10, and 50 nm), and total RNA was isolated for analysis by Northern blotting. Figure 4A shows representative samples from experiments performed to determine whether OA affected the cAMP-dependent mRNA expression of endogenous hCYP17. As depicted, (Bu) 2 cAMP significantly increased mRNA expression of hCYP17, and OA acts to inhibit this cAMP-evoked increase (Fig. 4B) . PV (5, 10, and 50 m) was found to have similar effects on cAMPstimulated hCYP17 mRNA expression (Fig. 4, C and D) .
Protein phosphatase mimics cAMP in inducing binding of the SF-1/p54
nrb /NonO/PSF complex to the hCYP17 promoter -PPase is a dual specificity phosphatase that dephosphorylates proteins that are phosphorylated on serine, threonine, FIG. 1. Inhibition of the MAPK pathway mimics the cAMP-inducible binding and cAMP-dependent transcriptional activation of hCYP17. A, EMSA analysis of binding of nuclear proteins to the Ϫ57/Ϫ38 region of the hCYP17 promoter. H295R cells were subcultured onto 100-mm dishes and incubated for 2 or 12 h in the presence or absence of 1 mM (Bu) 2 cAMP, 10 M PKI, and 25 M PD98059. Nuclear proteins were incubated with a 32 P-radiolabeled double-stranded oligonucleotide corresponding to region Ϫ57/Ϫ38 of the hCYP17 promoter. Lanes 1-6 are 2-h points, and lanes 7-12 are 12-h points. B, Transient transfection assays were performed as described in Materials and Methods. Twenty-four hours after transfection, cells were stimulated with (Bu) 2 cAMP and incubated for an additional 12-h. Luciferase activity and protein content were determined from the harvested cellular extracts. Data are expressed as RLU per microgram protein and are the mean of at least three separate experiments performed in triplicate. *, P Ͻ 0.05 (statistically different from vehicle-treated control). C, Northern blots of endogenous hCYP17 and GAP mRNA expression after 12 h exposure to (Bu) 2 nrb / NonO, and/or PSF promotes increased binding to the region Ϫ57/Ϫ38 of the hCYP17 promoter.
To determine whether SF-1, p54 nrb /NonO, and PSF are dephosphorylated after cAMP-stimulation in vivo, the proteins were immunoprecipitated from 32 P-labeled H295R nuclear extracts. Unexpectedly, stimulation with (Bu) 2 cAMP resulted in a decrease in the intensity of SF-1 (Fig. 5B) , indicating cAMP-mediated dephosphorylation of SF-1. No significant difference was seen in the amount of SF-1 immunoprecipitated, as measured by Western blotting (Fig. 5B,  lower panel) . Further, 32 P-labeled nuclear extracts isolated from cells that were in situ labeled were exposed to -PPase, followed by immunoprecipitation with anti-SF-1 or antiNonO antiserum. As shown in Fig. 5 , B and C, incubation of 32 P-labeled nuclear extracts with -PPase before immunoprecipitation resulted in a decrease in the intensity of the immunoprecipitated SF-1, further confirming the removal of a phosphate group(s) from the protein. Little effect of p54 nrb / NonO phosphorylation or dephosphorylation was observed.
Discussion
In the present study, we demonstrate that this cAMPinducible binding occurs via changes in the phosphorylation state of SF-1 that is partnering with p54 nrb /NonO and PSF, and interacting with the hCYP17 promoter. We show that inhibition of phosphatase activity (both serine/threonine and tyrosine) inhibits the cAMP-mediated increase in binding intensity of SF-1, PSF, and p54 nrb /NonO to region Ϫ57/ Ϫ38 of the hCYP17 promoter. We also found that the cAMPdependent increase in transcriptional activity of a reporter construct containing the first 57 bp of the hCYP17 promoter fused to the luciferase gene is attenuated by phosphatase inhibition. Finally, we show that agents that inhibit phosphatase activity attenuate the cAMP-stimulated increase in transcription of the endogenous hCYP17 gene. These findings demonstrate that dephosphorylation of one or more of the proteins that bind to the hCYP17 promoter is required for the maintenance of optimal steroidogenic activity in the adrenal cortex via ACTH/cAMP. SF-1 is expressed in all major steroid-producing tissues and is required for their development and differentiation. SF-1 binds as a monomer to its responsive elements located in the promoter of steroidogenic genes and is thus thought to be a key regulator of steroid hormone biosynthesis. Overexpression of SF-1 has been shown to greatly increase both basal and cAMP-dependent reporter gene expression for constructs prepared from the bovine CYP17, 3␤HSD, CYP11A, and CYP19 genes (8, 24 -27). The mechanism by which SF-1 conveys ACTH/cAMP-increased transcription is unclear; especially as SF-1 mRNA expression remains constant after elevation of ACTH/cAMP levels (28, 29). Studies have found that the MAPK pathway alters the expression of genes that are transcriptionally regulated by SF-1. Transcription of the glycoprotein hormone ␣-subunit is regulated by the release of GnRH via a MAPK-dependent pathway. The promoter of the glycoprotein hormone ␣-subunit is also regulated by SF-1 (30). One can speculate that the activation of SF-1 may involve ligand binding to the receptor. However, the existence of a ligand for SF-1 has not been confirmed. Thus, a model in which posttranslational modification of SF-1 or other proteins that interact with SF-1 to confer transcriptional activation of the steroid hydroxylase genes seems plausible.
SF-1 is phosphorylated on serine 203 by MAPK (18) . It is thought that this phosphorylation leads to increased cofactor recruitment, which then modulates the coordinate regulation of multiple SF-1 target genes (steroid hydroxylases) in response to hormone stimulation (18) . However, SF-1 was not found to be a cAMP-dependent phosphoprotein. We show here that both cAMP and the inhibition of the MAPK pathway can independently result in increased binding of SF-1, PSF, and p54 nrb /NonO to the hCYP17 promoter and also increase hCYP17 reporter gene activity. The cross-talk between the cAMP and MAPK pathways has been demonstrated in models of neuronal differentiation (31-33). It is unclear whether cross-talk occurs between the two pathways; however, our results suggest that the cAMP-mediated transcription may be independent of the MAPK pathway. However, based on our findings that PD98059 partially antagonized the stimulatory effect of (Bu) 2 cAMP, it is possible that the MAPK pathway and the ACTH/cAMP pathways may overlap.
Our present findings have demonstrated a role for phosphatase activity in the cAMP-dependent expression of hCYP17. We propose a mechanism for cAMP-dependent transcription of the hCYP17 gene where, after the release of ACTH from the anterior pituitary and the activation of adenylyl cyclase, the increase in intracellular cAMP causes the activation of PKA and the subsequent phosphorylation of a phosphatase, with both serine/threonine and tyrosine activity [plausibly an MAPK phosphatase (MKP)], that is involved in maintaining optimal steroidogenic capacity. Once activated, this phosphatase removes a phosphate from SF-1, thereby activating this nuclear receptor and alleviating the repression evoked by the binding of the corepressor mSin3A to PSF. Inactivation of the mSin3A/histone deacetylase corepressor system then results in increased affinity of the interaction of SF-1, p54 nrb /NonO, and PSF with the hCYP17 promoter, subsequently increasing hCYP17 gene transcription. Alternatively, the phosphatase (MKP) could be involved in the inactivation of the MAPK that maintains SF-1 constitutively phosphorylated (18) .
Recently, cAMP-induced increases in steroidogenic acute regulatory protein (StAR) mRNA has been found to be dependent upon phosphoprotein phosphatase activities (34). Using competitive RT-PCR, it was found that inhibition of phosphoprotein phosphatase-1 and -2A activities attenuated the forskolin-induced expression of StAR mRNA (34). We believe that hCYP17 regulation in H295R cells in response to cAMP has similar features.
In bovine adrenocortical cells, the prototypical morphological cell rounding observed upon treatment with ACTH or cAMP is blocked by the tyrosine phosphatase inhibitor sodium orthovanadate (35). It was hypothesized that the mechanism for cell detachment and disassembly of focal adhesions was mediated by PKA phosphorylation and activation of a phosphatase(s) in response to increased intracellular cAMP (35). Our model for the activation of phosphatase activity by PKA (Fig. 6) is very similar. However, one clear difference between bovine adrenocortical cells and human H295R cells is that ACTH/cAMP has never been shown in bovine cells to enhance transcription factor binding to bCYP17 or any other steroidogenic gene.
Recently, attempts have been made to probe the mechanism by which ACTH stimulates phosphatase activity. Rocchi et al. (36) have shown that ACTH stimulates phosphotyrosine phosphatase SHP2 (short heterodimer protein) in bovine adrenocortical cells. SHP2 is a cytosolic protein tyrosine phosphatase that is ubiquitously expressed and has been shown to act in response to a number of different growth factors, including epidermal growth factor and platelet-derived growth factor (37, 38). In an in vitro kinase assay SHP2 was found to be a target for PKA (36). Moreover, stimulation of 32 P-labeled bovine adrenocortical cells with ACTH resulted in increased SHP2 phosphorylation (36). The The regulation of MAPKs (specifically p42 and p44) has been studied in Y1 mouse adrenocortical cells (40). It was found that ACTH and basic fibroblast growth factor each increased MAPK kinase (MEK) activity (40). Furthermore, PD98059 blocked the activation of MEK and thus the phosphorylation of p42 and p44 by ACTH (40). These findings showing evidence for a negative influence of PKA on MEK activation are in contrast to our current work, where MAPK inhibition mimicked the stimulatory effects of cAMP on hCYP17 gene transcription. Time-course and dose-response studies are currently underway to further examine the effects of PD98059 on hCYP17 gene expression. It is possible that the discrepancy may be due to the difference in cell lines (murine Y1 vs. human H295R). We have also recently found that the cAMP-inducible binding of SF-1, PSF, and p54/NonO to the hCYP17 promoter only occurs when using nuclear extracts isolated from H295R cells and not Y1 cells (8a) .
The direct activation of phosphatases by tyrosine phosphorylation has been well documented (41, 42), whereas regulation of phosphatases by serine/threonine phosphorylation has been documented only indirectly (43, 44). Bouchard et al. (41) used peptide mapping and microsequencing to demonstrate the phosphorylation of protein tyrosine phosphatase 1C on tyrosine 538 after incubation with tyrosine kinase. The fact that both PV and OA act to attenuate cAMPinducible transcription factor binding, reporter activity, and endogenous hCYP17 mRNA expression suggests that PKA phosphorylates and activates both serine/threonine and tyrosine phosphatase activities (dual function phosphatase). Dual function phosphatases (known as MKPs) are a subclass of the protein tyrosine phosphatase gene superfamily that are selective for dephosphorylating phosphothreonine and phosphotyrosine residues within MEKs (20) .
In summary, we have demonstrated that the cAMP-stimulated increased binding intensity of the SF-1/p54 nrb / NonO/PSF complex to the Ϫ57/Ϫ38 region of the hCYP17 promoter is mediated by activation of serine/threonine and tyrosine phosphatase activity. Phosphatase activity mediates both the cAMP-dependent increases in reporter construct transcriptional activity and endogenous hCYP17 mRNA expression. Moreover, we have demonstrated that cAMP stimulation of H295R cells results in the dephosphorylation of SF-1, as measured by immunoprecipitation of SF-1 after in vivo labeling with [ 32 P]orthophosphate. We conclude that the cAMP-dependent transcriptional regulation of steroid hormone biosynthesis requires phosphatase activity.
